Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions

Waldenström macroglobulinemia is a rare lymphoplasmacytic malignancy characterized by bone marrow infiltration and monoclonal immunoglobulin M production. Despite its indolent clinical course, the disease exhibits considerable biological complexity driven by recurrent genetic alterations, dysregulated signaling pathways, and a supportive bone marrow microenvironment. The identification of MYD88 and CXCR4 mutations has significantly advanced understanding of disease pathogenesis, clonal evolution, and treatment response. Additional insights from cytogenetic, epigenetic, and microRNA studies have further refined the molecular landscape of this disorder. These advances have translated into improved therapeutic strategies, particularly with the introduction of Bruton's tyrosine kinase inhibitors, although treatment resistance remains a clinical challenge. Other targeted approaches, including BCL2 and proteasome inhibition, offer additional options for personalized therapy. Ongoing integration of molecular and microenvironmental data is expected to enhance risk stratification and support the development of more effective, tailored treatment strategies.